Claims
- 1. A method of treating a metabolic disorder in a person induced by treatment of the person with an HIV protease inhibitor, comprising administering to the person a therapeutically effective dose of an insulin receptor-activating compound that is not insulin, or a pharmaceutically acceptable salt thereof.
- 2. The method of claim 1, where the metabolic disorder induced by treatment with an HIV protease inhibitor is selected from the group consisting of insulin resistance, hyperglycemia, diabetes, ketoacidosis, lipodystrophy, and hypertriglyceridemia.
- 3. The method of claim 1, where the insulin receptor-activating compound is a compound of Formula I
- 4. The method of claim 3, wherein no Y is linked to a naphthalene ring via an azo linkage in the compound.
- 5. The method of claim 3, wherein, where R1 and R2 are both —SO2OH,
(i) no Y is —SO2OH; (ii) neither R5 nor R6 is —SO2OR8 or —OSO2R8; and (iii) where no (Y)x is (Y′)x′, wherein x′ is 1 or 2 and Y′ is a halo radical, R5 and R6 are not both selected from the group consisting of hydroxy and hydrogen.
- 6. The method of claim 1, where the insulin receptor-activating compound is a compound of Formula II
- 7. The method of claim 1, where the insulin receptor-activating compound is a compound of Formula III
- 8. The method of claim 1, where the insulin receptor-activating compound is a compound of Formula IV
- 9. The method of claim 1, where the insulin receptor-activating compound is a compound of Formula V
- 10. The method of claim 1, where the insulin receptor-activating compound is a compound of Formula VI
- 11. The method of claim 1, where the insulin receptor-activating compound is a compound of Formula VII
- 12. The method of claim 1, further comprising administering a therapeutically effective amount of an additional formn of treatment for insulin resistance, hyperglycemia, diabetes, ketoacidosis, lipodystrophy, or hypertriglyceridemia.
- 13. The method of claim 12, wherein the therapeutically effective amount of the additional form of treatment when administered in combination with a compound of the invention is less than the amount of the additional form of treatment that would be therapeutically effective if delivered to the patient alone.
- 14. The method of claim 12, wherein the additional form of treatment is insulin.
- 15. The method of claim 12, wherein the additional form of treatment is an insulin analog.
- 16. The method of claim 14, wherein the therapeutically effective amount of insulin or insulin analog when administered in combination with a compound of the invention is less than the amount of insulin or insulin analog which would be therapeutically effective if delivered to the patient alone.
- 17. The method of claim 1, comprising administering two of the compounds of claims 3-11.
- 18. The method of claim 1, where the insulin receptor-activating compound is
- 19. The method of claim 1, where the insulin receptor-activating compound is
- 20. The method of claim 1, where the insulin receptor-activating compound is
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the priority under 35 USC 119(e) of U.S. Provisional Application No. 60/239,636, filed Oct. 11, 2000, which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60239636 |
Oct 2000 |
US |